Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,147
Employees1,147
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,147
Employees1,147

EXEL Key Statistics

Market cap
11.00B
Market cap11.00B
Price-Earnings ratio
18.57
Price-Earnings ratio18.57
Dividend yield
Dividend yield
Average volume
3.58M
Average volume3.58M
High today
$39.15
High today$39.15
Low today
$37.82
Low today$37.82
Open price
$38.18
Open price$38.18
Volume
2.43M
Volume2.43M
52 Week high
$49.62
52 Week high$49.62
52 Week low
$27.86
52 Week low$27.86

EXEL News

Simply Wall St 4d
Is EXEL’s Portfolio Strategy Being Tested by Mixed Results from Zanzalintinib Trial?

Exelixis recently announced detailed results from its phase 3 STELLAR-303 trial, showing that the combination of zanzalintinib and atezolizumab achieved a 20% r...

Is EXEL’s Portfolio Strategy Being Tested by Mixed Results from Zanzalintinib Trial?
TipRanks 4d
Exelixis price target lowered to $44 from $50 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Exelixis (EXEL) to $44 from $50 and keeps an Overweight rating on the shares after company presented detailed...

TipRanks 4d
Exelixis upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Exelixis (EXEL) to Outperform from Market Perform with a $48 price target Published first on TheFly – the ultimate source for real-time, marke...

Analyst ratings

62%

of 21 ratings
Buy
61.9%
Hold
38.1%
Sell
0%

More EXEL News

Nasdaq 4d
Validea John Neff Strategy Daily Upgrade Report - 10/21/2025

The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persiste...

Validea John Neff Strategy Daily Upgrade Report - 10/21/2025
Benzinga 5d
Why Is Cancer Focused Exelixis Stock Falling On Monday? - Exelixis - Benzinga

...

Why Is Cancer Focused Exelixis Stock Falling On Monday? - Exelixis - Benzinga
Benzinga 5d
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results

Exelixis Inc. (NASDAQ:EXEL) stock is trading lower on Monday after the company shared detailed results from the STELLAR-303 Phase 3 trial. The trial evaluated...

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results
Benzinga 5d
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Monday. Shares of Olema Pharmaceuticals Inc (NASDAQ:OLMA) fell 18.3% t...

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
TipRanks 6d
Exelixis announces results from analysis of CABINET Phase 3 trial of CABOMETYX

Exelixis (EXEL) announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX versus placebo in patients with previously...

Simply Wall St 6d
A Look at Exelixis Valuation After New CABINET Trial Data on CABOMETYX in Neuroendocrine Tumors

Exelixis (EXEL) just shared new results from a subgroup analysis of its phase 3 CABINET trial. The study showed that CABOMETYX substantially reduced disease pro...

A Look at Exelixis Valuation After New CABINET Trial Data on CABOMETYX in Neuroendocrine Tumors

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.